compound 31 [PMID: 22902653]   Click here for help

GtoPdb Ligand ID: 8117

Compound class: Synthetic organic
Comment: Compound 31 was designed as an inhibitor of the LIM domain kinases LIMK1 and LIMK2 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 143.05
Molecular weight 461.16
XLogP 1.7
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCNC(=O)Nc1ncc(s1)c1cc(nc(n1)c1cnccn1)c1c(C)cc(cc1C)OC
Isomeric SMILES CCNC(=O)Nc1ncc(s1)c1cc(nc(n1)c1cnccn1)c1c(C)cc(cc1C)OC
InChI InChI=1S/C23H23N7O2S/c1-5-25-22(31)30-23-27-12-19(33-23)16-10-17(20-13(2)8-15(32-4)9-14(20)3)29-21(28-16)18-11-24-6-7-26-18/h6-12H,5H2,1-4H3,(H2,25,27,30,31)
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
LIM domain kinases and the related testis-specific protein kinases are known to phosphorylate the actin-binding protein cofilin [1,4,6]. This phosphorylation has an inhibitory effect on cofilin's interaction with F-actin and acts to depolymerise actin, having profound effects on the cytoskeleton [3,5]. LIM kinase inhibitors are being pursued as anti-cancer agents with effects on the invasiveness and metastatic capacity of tumour cells.